Fred Alger Management, LLC Fibrogen Inc Transaction History

Fred Alger Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$40.47 - $45.5 $728,460 - $819,000	-18,000 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $116,500 - $229,800	-5,000 Reduced 21.74%	18,000 $626,000
Q3 2019 Nov 14, 2019	SELL	$36.98 - $48.45 $73,960 - $96,900	-2,000 Reduced 8.0%	23,000 $851,000
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $70,260 - $111,060	2,000 Added 8.7%	25,000 $1.13 Million
Q1 2019 May 14, 2019	BUY	$42.83 - $59.91 $128,490 - $179,730	3,000 Added 15.0%	23,000 $1.25 Million
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $759,400 - $1.2 Million	20,000 New	20,000 $926,000
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $281,500 - $336,250	-5,000 Closed	0 $0
Q2 2018 Jul 19, 2018	BUY	$44.9 - $64.95 $224,500 - $324,750	5,000 New	5,000 $313,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.